Pseudomonas aeruginosa infection and vaccination in the rat

Kostiala, Anja A. I.

doi:10.1099/00222615-13-2-201

Cited by 6 publications

(1 citation statement)

References 37 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In mice, rats, or pigs, acute cutaneous P. aeruginosa infection models have been established but acute systemic infection require high inoculum of P. aeruginosa cells and not as popular as burn wound infections, which require much less bacteria due to immunosuppression. 5 × 10 6 cells of the hyper‐virulent PA14 strain were needed to establish persistent cutaneous or invasive infection in CD1 mice [23] while 4.3 × 10 8 and 3.4 × 10 10 CFU for two P. aeruginosa strains were determined to be essential for 50% lethality in Sprague–Dawley rats [59]. Siderophores pyoverdine and pyochelin and type III secretion system have been shown to be critical for development of dermonecrosis and dissemination of the PA14 strain.…”

Section: Skin and Soft Tissue Infectionsmentioning

confidence: 99%

Evaluation of Pseudomonas aeruginosa pathogenesis and therapeutics in military‐relevant animal infection models

Bobrov

Getnet

Swierczewski

et al. 2021

APMIS

View full text Add to dashboard Cite

Modern combat-related injuries are often associated with acute polytrauma. As a consequence of severe combat-related injuries, a dysregulated immune response results in serious infectious complications. The gram-negative bacterium Pseudomonas aeruginosa is an opportunistic pathogen that often causes life-threatening bloodstream, lung, bone, urinary tract, and wound infections following combat-related injuries. The rise in the number of multidrug-resistant P. aeruginosa strains has elevated its importance to civilian clinicians and military medicine. Development of novel therapeutics and treatment options for P. aeruginosa infections is urgently needed. During the process of drug discovery and therapeutic testing, in vivo testing in animal models is a critical step in the bench-to-bedside approach, and required for Food and Drug Administration approval. Here, we review current and past literature with a focus on combat injuryrelevant animal models often used to understand infection development, the interplay between P. aeruginosa and the host, and evaluation of novel treatments. Specifically, this review focuses on the following animal infection models: wound, burn, bone, lung, urinary tract, foreign body, and sepsis.

show abstract

Section: Skin and Soft Tissue Infectionsmentioning

confidence: 99%